PT-141

PT-141, also known as bremelanotide, is a synthetic peptide that mimics a natural hormone to increase sexual desire and arousal Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder. It was approved by the FDA in 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), a condition marked by low sexual desire that causes distress Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder+1. Unlike drugs that work by increasing genital blood flow, PT-141 acts on specific receptors in the brain (MC3R and MC4R) to boost sexual motivation and responsiveness Safety Profile of Bremelanotide Across the Clinical Development Program+1.

PT-141 is a melanocortin receptor agonist, meaning it binds to and activates MC3R and MC4R receptors in the central nervous system Safety Profile of Bremelanotide Across the Clinical Development Program+1. These receptors are part of the melanocortin system, which influences sexual motivation, appetite, and stress responses. When PT-141 stimulates MC4R in hypothalamic and limbic brain regions, it enhances the activity of dopamine pathways linked to desire and arousal The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women+1. This central mechanism explains why PT-141 can increase sexual thoughts and receptivity independent of direct effects on genital blood vessels An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist+1.

In randomized controlled trials involving over 1,200 premenopausal women with HSDD, PT-141 consistently improved scores on the Female Sexual Function Index (FSFI) and reduced distress related to low desire compared to placebo Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder+1. However, the absolute benefit was modest. Meta-analyses report that PT-141 improved sexual desire and arousal subscales and decreased distress, but the effect sizes were small to moderate Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options. Some researchers have questioned whether the statistical improvements translate to meaningful real-world changes, especially when balanced against common side effects Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder.

Clinical studies of PT-141 have used an on-demand subcutaneous dosing regimen. The most studied protocol is 1.75 mg injected under the skin about 45 minutes before sexual activity, with a limit of one dose per day and no more than eight doses per month Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder+1. This pattern reflects the drug's rapid onset and relatively short duration of action, tailored to episodic sexual activity rather than daily symptom suppression. Because nausea is a common side effect, many protocols begin with a lower test dose of 0.5 to 1.0 mg to gauge individual tolerance before advancing to the full dose Safety Profile of Bremelanotide Across the Clinical Development Program+1.

Lyophilized PT-141 is usually sold in 10 mg vials for research purposes. Reconstitution is performed with bacteriostatic water to allow multiple uses from a single vial, as sterile water only preserves the solution for about a week. The resulting solution should be kept refrigerated and protected from light. While the peptide is stable in dry form for months if frozen, once mixed it is best used within 30 days. An interactive calculator on this page can help determine the exact volumes needed for a desired dose.

Because PT-141 raises blood pressure transiently and causes nausea, it interacts with several drug classes. Combining PT-141 with PDE5 inhibitors like sildenafil is common in male research but may amplify headache, flushing, and blood pressure effects Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options+1. Alcohol worsens nausea and reduces tolerability, so minimal intake is advised on dosing days Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. Antihypertensive medications may blunt or alter the blood pressure response, requiring careful monitoring Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. There is no strong evidence of metabolic drug interactions, as PT-141 is not metabolized by liver enzymes involved in typical drug-drug interactions An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.

PT-141 is used on an as-needed basis rather than in continuous cycles. The approved regimen caps use at eight doses per month, and clinical trials employed PRN dosing, not daily administration Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder+2. Some users report diminished response with overly frequent use, so a break of one to two weeks after a period of regular dosing is a common community practice to maintain effectiveness. There is no formal tolerance data, but intermittent use reflects the episodic nature of the condition being treated.

PT-141 is often stacked with other compounds to enhance sexual response. The most reported combination is with PDE5 inhibitors (sildenafil or tadalafil) for men, since PT-141 works centrally on desire while PDE5 inhibitors improve erectile function peripherally Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response+1. Some practitioners also explore pairing PT-141 with oxytocin or kisspeptin to further boost libido, though human data are lacking. Caution is needed because nausea and blood pressure effects can be additive Safety Profile of Bremelanotide Across the Clinical Development Program+1.

Bremelanotide, sold under the brand name Vyleesi, is an FDA-approved prescription medicine for premenopausal women with acquired, generalized HSDD Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder+1. It is not a controlled substance in the United States, but it is available only through a healthcare provider. Outside the US, its regulatory status varies; it is not approved in the European Union or Australia as of the latest available data Bremelanotide: First Approval+1. For competitive athletes, the World Anti-Doping Agency (WADA) has not explicitly listed bremelanotide, but its peptide nature and melanocortin activity place it in a gray area, and off-label use could risk an anti-doping rule violation An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder.

The most common side effects of PT-141 are nausea (occurring in up to 40% of users), facial flushing, and headache Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder+1. These are typically mild to moderate and tend to decrease with repeated use. Transient increases in blood pressure have been documented, so individuals with uncontrolled hypertension or cardiovascular disease should avoid it Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide+1. Less common effects include darkening of the skin or gums with prolonged use, a result of melanocortin receptor activation in pigment cells Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder. PT-141 is not recommended during pregnancy, while breastfeeding, or in people with severe kidney or liver impairment Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options+1.